Magnesium Sulfate Effects on Onset and Duration of Low Dose Rocuronium in Patients Undergoing Laparoscopic Cholecystectomy
Effects of Magnesium Sulfate on Onset and Duration of Low Dose Rocuronium in Patients Undergoing Laparoscopic Cholecystectomy
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Assiut, Egypt, 71121
- Assiut University Hospitals
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- American Society of Anesthesiologists physical status 1 or 2.
- BMI of 25-34.9 kg/m2.
- Patients scheduled for laparoscopic cholecystectomy.
Exclusion Criteria:
- Severe respiratory or cardiac disease.
- Hepatic or renal function impairment.
- Neuromuscular disease.
- Patients on medications affecting neuromuscular function.
- Patients with known allergy to the drugs.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Standard dose Rocuronium
Pretreatment of saline 100ml then giving Rocuronium 0.6 mg/kg at induction of anesthesia.
|
Patients in each group receive 0.9% normal saline (total volume 100 ml) alone intravenously for 5 min before induction of anesthesia
0.6 mg/kg of Rocuronium given with induction of anesthesia
|
|
Active Comparator: Low dose Rocuronium
Pretreatment of saline 100ml then giving Rocuronium 0.45 mg/kg at induction of anesthesia.
|
Patients in each group receive 0.9% normal saline (total volume 100 ml) alone intravenously for 5 min before induction of anesthesia
0.45 mg/kg of Rocuronium given with induction of anesthesia
|
|
Active Comparator: Low dose Rocuronium + Magnesium Sulfate
Pretreatment of Magnesium sulfate 30 mg/kg then giving Rocuronium 0.45 mg/kg at induction of anesthesia.
|
0.45 mg/kg of Rocuronium given with induction of anesthesia
Patients in each group receive Magnesium sulfate 30 mg/kg in 0.9% normal saline (total volume 100 ml) intravenously for 5 min before induction of anesthesia
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The time of onset the action of Rocuronium
Time Frame: Time from injection of Rocuronium till T1 suppression more than 95% up to 10 minutes.
|
by using the TOF watch nerve stimulator
|
Time from injection of Rocuronium till T1 suppression more than 95% up to 10 minutes.
|
|
The time at which Maximal suppression
Time Frame: Time from the injection of Rocuronium to T1 maximal suppression time (TOF=0) up to an hour.
|
by using the TOF watch nerve stimulator
|
Time from the injection of Rocuronium to T1 maximal suppression time (TOF=0) up to an hour.
|
|
Reversal of Rocuronium
Time Frame: Time from injection of Rocuronium till reversal of T1 (TOF=25%) around an hour after induction of anesthesia
|
by using the TOF watch nerve stimulator
|
Time from injection of Rocuronium till reversal of T1 (TOF=25%) around an hour after induction of anesthesia
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Intubation condition
Time Frame: Within 10 minutes after induction of anesthesia
|
to score intubation condition on the basis of 6 items: Jaw relaxation, laryngoscopy, vocal cord position, moving of limbs, coughing & change in heart rate.
|
Within 10 minutes after induction of anesthesia
|
|
Surgical condition
Time Frame: During surgery
|
to score a surgical condition according to 7 point likert scale
|
During surgery
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Chair: Nawal Abdelaziz Gadelrab, Professor, Assiut University
- Study Director: Ola Mahmoud Wahba, Lecturer, Assiut University Hospitals
- Principal Investigator: Ahmed Hamada Hamed Amin, Resident, Assiut University Hospitals
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Arrhythmia Agents
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Anesthetics
- Membrane Transport Modulators
- Anticonvulsants
- Calcium-Regulating Hormones and Agents
- Reproductive Control Agents
- Calcium Channel Blockers
- Neuromuscular Agents
- Tocolytic Agents
- Neuromuscular Nondepolarizing Agents
- Neuromuscular Blocking Agents
- Magnesium Sulfate
- Rocuronium
Other Study ID Numbers
Other Study ID Numbers
- 01MgRo
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.